Idiopathic Pulmonary Fibrosis Clinical Trial Landscape
Data updated: May 20, 2026
303 clinical trials tracked since 2008
Idiopathic Pulmonary Fibrosis is being studied across 303 clinical trials registered since 2008, with 85 programs currently active. The competitive pipeline includes 19 active Phase 3 trials, 43 active Phase 2 trials, and 27 active Phase 1 trials. Top industry sponsors include Boehringer Ingelheim, Bristol-Myers Squibb, Sunshine Lake Pharma Co., Ltd..
85 active
/
303 total (since 2008)
27
Phase 1 Active
111 total
43
Phase 2 Active
148 total
19
Phase 3 Active
53 total
1
Phase 4 Active
10 total
Top Industry Sponsors
Sorted by active Active Done Failed
Boehringer Ingelheim 4 16 2
Bristol-Myers Squibb 3 5 2
Sunshine Lake Pharma Co., Ltd. 3 5 0
Guangdong Hengrui Pharmaceutical Co., Ltd 3 3 0
Haisco Pharmaceutical Group Co., Ltd. 3 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06238622 RECRUITING
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Boehringer Ingelheim n=1,700
NCT05943535 RECRUITING
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics n=698
NCT07201922 RECRUITING
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Boehringer Ingelheim n=80
NCT06025578 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Bristol-Myers Squibb n=1,057
NCT07082842 RECRUITING
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Sunshine Lake Pharma Co., Ltd. n=472
+ 48 more Phase 3 trials — see full database below
Idiopathic Pulmonary Fibrosis — Trials Started by Year (last 10 years)
2016 15
2017 8
2018 16
2019 13
2020 24
2021 25
2022 23
2023 31
2024 21
2025 25
2026 26
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Boehringer Ingelheim 22
Bristol-Myers Squibb 10
Sunshine Lake Pharma Co., Ltd. 8
Guangdong Hengrui Pharmaceutical Co., Ltd 6
Haisco Pharmaceutical Group Co., Ltd. 4
Avalyn Pharma Inc. 3
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. 3
United Therapeutics 7
Endeavor Biomedicines, Inc. 4
PureTech 2
Active Trials by Phase
Phase 1 27
Phase 2 43
Phase 3 19
Phase 4 1
Enrollment Size Distribution
1-50 131
51-200 106
201-500 33
501-1k 15
1k+ 8
All Industry Sponsors
Sorted by active Active Done Failed
Boehringer Ingelheim 4 16 2
Bristol-Myers Squibb 3 5 2
Sunshine Lake Pharma Co., Ltd. 3 5 0
Guangdong Hengrui Pharmaceutical Co., Ltd 3 3 0
Haisco Pharmaceutical Group Co., Ltd. 3 1 0
Avalyn Pharma Inc. 3 0 0
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. 3 0 0
United Therapeutics 2 3 2
Endeavor Biomedicines, Inc. 2 2 0
PureTech 2 0 0
Daewoong Pharmaceutical Co. LTD. 1 3 0
Rein Therapeutics 1 2 0
Vicore Pharma AB 1 2 0
Trevi Therapeutics 1 2 0
Chiesi Farmaceutici S.p.A. 1 2 0
NCT06238622 RECRUITING
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Boehringer Ingelheim n=1,700
NCT07441408 NOT YET RECRUITING
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Bristol-Myers Squibb n=2,277
NCT05943535 RECRUITING
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics n=698
NCT04905693 ENROLLING BY INVITATION
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics n=1,850
NCT07201922 RECRUITING
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Boehringer Ingelheim n=80
NCT06025578 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Bristol-Myers Squibb n=1,057
NCT07082842 RECRUITING
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Sunshine Lake Pharma Co., Ltd. n=472
NCT07520110 NOT YET RECRUITING
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
University of Massachusetts, Worcester n=800
NCT07519070 NOT YET RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd. n=420
NCT07503587 NOT YET RECRUITING
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd. n=378
NCT06003426 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb n=1,255
NCT07299695 RECRUITING
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Argyrios Tzouvelekis n=196
NCT07464912 RECRUITING
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Beijing Tide Pharmaceutical Co., Ltd n=508
NCT05674994 RECRUITING
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Fondation Hôpital Saint-Joseph n=110
NCT07284602 NOT YET RECRUITING
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
PureTech n=1,100
NCT04965298 RECRUITING
Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
Norfolk and Norwich University Hospitals NHS Foundation Trust n=298
NCT04948203 ACTIVE NOT RECRUITING
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
University of Chicago n=60
NCT06125327 RECRUITING
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Guangzhou JOYO Pharma Co., Ltd n=210
NCT04541680 RECRUITING
Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
Assistance Publique - Hôpitaux de Paris n=250
NCT04429516 COMPLETED
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Royal Brompton & Harefield NHS Foundation Trust n=44
NCT04708782 COMPLETED
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics n=598
NCT04300920 COMPLETED
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
Fernando J Martinez n=202
NCT05321069 COMPLETED
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim n=1,177
NCT05255991 COMPLETED
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics n=597
NCT04979884 COMPLETED
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
Alexandria University n=66
NCT00631475 COMPLETED
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Actelion n=128
NCT03955146 TERMINATED
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Kyntra Bio n=393
NCT04419558 TERMINATED
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Kyntra Bio n=372
NCT04594707 TERMINATED
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche n=117
NCT04552899 TERMINATED
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche n=665
NCT03267108 TERMINATED
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
Bellerophon Pulse Technologies n=145
NCT02633293 TERMINATED
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
United Therapeutics n=243
NCT03711162 TERMINATED
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Galapagos NV n=525
NCT03733444 TERMINATED
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Galapagos NV n=781
NCT02630316 COMPLETED
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
United Therapeutics n=326
NCT02460588 COMPLETED
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Assistance Publique - Hôpitaux de Paris n=120
NCT01619085 COMPLETED
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim n=752
NCT02759120 TERMINATED
CleanUP IPF for the Pulmonary Trials Cooperative
Weill Medical College of Cornell University n=513
NCT03208933 COMPLETED
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
Hoffmann-La Roche n=60
NCT02739165 COMPLETED
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Asahi Kasei Therapeutics Corporation n=74
NCT02802345 COMPLETED
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
Boehringer Ingelheim n=274
NCT00981747 TERMINATED
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
Alicia Gerke n=12
NCT01979952 COMPLETED
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim n=113
NCT01777737 TERMINATED
Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=3
NCT01366209 COMPLETED
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Genentech, Inc. n=555
NCT00662038 COMPLETED
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Genentech, Inc. n=1,058
NCT01335464 COMPLETED
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Boehringer Ingelheim n=515
NCT01335477 COMPLETED
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Boehringer Ingelheim n=551
NCT00650091 COMPLETED
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Duke University n=264
NCT00957242 TERMINATED
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
Duke University n=145
NCT00879229 TERMINATED
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Gilead Sciences n=40
NCT00768300 TERMINATED
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Gilead Sciences n=494
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only